{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:55:53Z","timestamp":1775804153032,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Guanylyl cyclase C (GCC) agonists, including linaclotide and plecanatide, induce prosecretory and analgesic effects by elevating cGMP levels in the intestinal lumen, rendering them significant treatment alternatives for constipation-predominant irritable bowel syndrome (IBS-C). Nonetheless, disparities in efficacy and safety across medications and dosages necessitate a thorough assessment using systematic reviews and meta-analyses, primarily focusing on composite efficacy endpoints approved by the U.S. Food and Drug Administration (FDA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search of PubMed, Embase, the Cochrane Library, Web of Science, and\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      databases was conducted to identify randomized controlled trials comparing the aforementioned GCC agonists with placebo for the treatment of IBS-C. The search timeframe spans from the establishment of each database to 7 September 2025. Three researchers independently performed literature screening, data extraction, and methodological quality assessment (using the Cochrane Risk of Bias Assessment Tool). The primary endpoint is the proportion of patients achieving the FDA composite endpoint. Secondary endpoints include indicators related to abdominal pain and constipation. The safety outcome was the incidence of diarrhea. Statistical analyses were performed using RevMan 5.4 and Stata 18.0 software.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 6 linaclotide and 3 plecanatide trials were included, involving 5,718 patients with IBS-C. Compared with placebo, GCC agonists significantly increased the proportion of patients achieving the FDA composite endpoint (linaclotide 290\u00a0\u03bcg [relative risk (RR) = 1.78, 95% CI 1.51\u20132.09]; plecanatide 3\u00a0mg [RR = 1.63, 95% CI 1.35\u20131.96]; plecanatide 6\u00a0mg [RR = 1.67, 95% CI 1.36\u20132.05]). GCC agonists also demonstrated significant advantages across all secondary outcome measures. However, the incidence of diarrhea was significantly higher in both drug groups compared to the placebo group (linaclotide 290\u00a0\u03bcg [relative risk (RR) = 6.20, 95% CI 4.39\u20138.76]; plecanatide 3\u00a0mg [RR = 5.29, 95% CI 1.59\u201317.64]; plecanatide 6\u00a0mg [RR = 4.00, 95% CI 1.52\u201310.51]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Linaclotide and plecanatide are effective medications for treating IBS-C, significantly improving both abdominal pain and constipation symptoms while increasing the risk of diarrhea. Their efficacy and safety should be carefully weighed when used clinically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251168079<\/jats:ext-link>\n                      , Identifier CRD420251168079.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1761301","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:00:29Z","timestamp":1775800829000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Guanylyl cyclase C agonists (linaclotide and plecanatide) in patients with irritable bowel syndrome with constipation: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Zihao","family":"Zhou","sequence":"first","affiliation":[{"name":"School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanlin","family":"Li","sequence":"additional","affiliation":[{"name":"School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyuan","family":"Tu","sequence":"additional","affiliation":[{"name":"School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Mianyang Hospital of Traditional Chinese Medicine","place":["Mianyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Defu","family":"Liao","sequence":"additional","affiliation":[{"name":"School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyan","family":"He","sequence":"additional","affiliation":[{"name":"School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiren","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyu","family":"Li","sequence":"additional","affiliation":[{"name":"School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zugang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Mianyang Hospital of Traditional Chinese Medicine","place":["Mianyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangchun","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Mianyang Hospital of Traditional Chinese Medicine","place":["Mianyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.cgh.2019.08.016","article-title":"Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey","volume":"17","author":"Ballou","year":"2019","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clinical Epidemiology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"718356","DOI":"10.3389\/fnut.2021.718356","article-title":"Inflammatory and microbiota-related regulation of the intestinal epithelial barrier","volume":"8","author":"Barbara","year":"2021","journal-title":"Front. Nutrition"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","article-title":"Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis","volume":"155","author":"Black","year":"2018","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e00295","DOI":"10.1002\/prp2.295","article-title":"Therapeutically targeting guanylate cyclase\u2010C: computational modeling of plecanatide, a uroguanylin analog","volume":"5","author":"Brancale","year":"2017","journal-title":"Pharmacol. Res. and Perspect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41395-018-0026-7","article-title":"Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials","volume":"113","author":"Brenner","year":"2018","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.14309\/ajg.0000000000002064","article-title":"Linaclotide reduced response time for irritable bowel syndrome with constipation symptoms: analysis of 4 randomized controlled trials","volume":"118","author":"Brenner","year":"2023","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrgastro.2014.103","article-title":"Neuroplasticity and dysfunction after gastrointestinal inflammation","volume":"11","author":"Brierley","year":"2014","journal-title":"Nat. Reviews Gastroenterology and Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","article-title":"Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract","volume":"86","author":"Bryant","year":"2010","journal-title":"Life Sciences"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s10620-013-2953-x","article-title":"Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide","volume":"59","author":"Busby","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ejphar.2010.09.019","article-title":"Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit","volume":"649","author":"Busby","year":"2010","journal-title":"Eur. Journal Pharmacology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1124\/jpet.112.199430","article-title":"Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation","volume":"344","author":"Busby","year":"2013","journal-title":"J. Pharmacology Experimental Therapeutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2013.08.017","article-title":"Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3\u2032, 5\u2032-monophosphate","volume":"145","author":"Castro","year":"2013","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/s0002-9270(01)02651-x","article-title":"Alterations in cerebral potentials evoked by rectal distension in irritable bowel syndrome","volume":"96","author":"Chan","year":"2001","journal-title":"Am. Journal Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.14309\/ajg.0000000000001334","article-title":"Efficacy of linaclotide in reducing abdominal symptoms of bloating, discomfort, and pain: a phase 3B trial using a novel abdominal scoring system","volume":"116","author":"Chang","year":"2021","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.14309\/ajg.0000000000000967","article-title":"Randomized trial of 2 delayed-release formulations of linaclotide in patients with irritable bowel syndrome with constipation","volume":"116","author":"Chey","year":"2021","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.semerg.2020.07.010","article-title":"Is the diet low in FODMAP really effective and safe for irritable bowel syndrome? a scoping review","volume":"46","author":"Domingo","year":"2020","journal-title":"Semergen"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features, and rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1053\/gast.2002.37095","article-title":"AGA technical review on irritable bowel syndrome","volume":"123","author":"Drossman","year":"2002","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/MCG.0b013e318189a7f9","article-title":"International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit","volume":"43","author":"Drossman","year":"2009","journal-title":"J. Clinical Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"312-e84","DOI":"10.1111\/j.1365-2982.2009.01385.x","article-title":"Guanylate cyclase C\u2010mediated antinociceptive effects of linaclotide in rodent models of visceral pain","volume":"22","author":"Eutamene","year":"2010","journal-title":"Neurogastroenterol. and Motil."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41395-018-0084-x","article-title":"American college of gastroenterology monograph on management of irritable bowel syndrome","volume":"113","author":"Ford","year":"2018","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e121841","DOI":"10.1172\/jci.insight.121841","article-title":"Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction","volume":"3","author":"Grundy","year":"2018","journal-title":"JCI Insight"},{"key":"B26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.mpaic.2019.07.014","article-title":"Visceral pain","volume":"81","author":"Grundy","year":"2019","journal-title":"Annu. Review Physiology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the journal of clinical epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clinical Epidemiology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/s12325-017-0633-5","article-title":"The better understanding and recognition of the disconnects, experiences, and needs of patients with chronic idiopathic constipation (BURDEN-CIC) study: results of an online questionnaire","volume":"34","author":"Harris","year":"2017","journal-title":"Adv. Therapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","article-title":"The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects","volume":"17","author":"Hungin","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.27.1_supplement.lb426","volume-title":"Efficacy of inulin enriched yogurt on bowel habits in patients with irritable bowel syndrome with constipation: a pilot study","author":"Isakov","year":"2013"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/jama.2014.2078","article-title":"Over-the-counter laxatives","volume":"312","author":"Jin","year":"2014","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston","year":"2010","journal-title":"Gastroenterology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13643-016-0259-8","article-title":"Evaluation of the cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews","volume":"5","author":"J\u00f8rgensen","year":"2016","journal-title":"Syst. Reviews"},{"key":"B34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pain.2004.10.005","article-title":"Characteristics of rectal perception are altered in irritable bowel syndrome","volume":"113","author":"Kwan","year":"2005","journal-title":"Pain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/00325481.1990.11704723","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cgh.2020.03.056","article-title":"Management of chronic abdominal distension and bloating","volume":"19","author":"Lacy","year":"2021","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.7748\/phc.18.4.24.s22","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1172\/jci76304","article-title":"Gut\/brain axis and the microbiota","volume":"125","author":"Mayer","year":"2015","journal-title":"J. Clinical Investigation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4740907","DOI":"10.1155\/2016\/4740907","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation","volume":"2016","author":"Mezzasalma","year":"2016","journal-title":"BioMed Research International"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1038\/ajg.2014.282","article-title":"Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C): 1831","volume":"109","author":"Miner","year":"2014","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ajg.2016.611","article-title":"A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation","volume":"112","author":"Miner","year":"2017","journal-title":"Official Journal Am. Coll. Gastroenterology ACG"},{"key":"B43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00006842-200105000-00006","article-title":"Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation","volume":"63","author":"Naliboff","year":"2001","journal-title":"Biopsychosoc. Sci. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1053\/j.gastro.2005.03.008","article-title":"A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders","volume":"128","author":"Pezzone","year":"2005","journal-title":"Gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s12325-018-0733-x","article-title":"Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire","volume":"35","author":"Quigley","year":"2018","journal-title":"Adv. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao","year":"2012","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.14309\/ajg.0000000000001687","article-title":"Mechanisms of action of current pharmacologic options for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation","volume":"117","author":"Sayuk","year":"2022","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e13762","DOI":"10.1111\/nmo.13762","article-title":"European society of neurogastroenterology and motility guidelines on functional constipation in adults","volume":"32","author":"Serra","year":"2020","journal-title":"Neurogastroenterol. and Motil."},{"key":"B50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/ajg.2017.495","article-title":"Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis","volume":"113","author":"Shah","year":"2018","journal-title":"Official Journal Am. Coll. Gastroenterology| ACG"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/s0002-9270(01)02515-1","article-title":"Visceral afferent hypersensitivity in irritable bowel syndrome\u2014evaluation by cerebral evoked potential after rectal stimulation","volume":"96","author":"Sinhamahapatra","year":"2001","journal-title":"Am. Journal Gastroenterology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity","volume":"316","author":"Stuck","year":"1998","journal-title":"BMJ Br. Med. J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1159\/000335767","article-title":"Uroguanylin regulates net fluid secretion via the NHE2 isoform of the Na+\/H+ exchanger in an intestinal cellular model","volume":"28","author":"Toriano","year":"2011","journal-title":"Cell. Physiology Biochem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1073\/pnas.95.4.1466","article-title":"Membrane targeting of cGMP-dependent protein kinase is required for cystic fibrosis transmembrane conductance regulator Cl\u2212 channel activation","volume":"95","author":"Vaandrager","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/jgh.14086","article-title":"Linaclotide in irritable bowel syndrome with constipation: a phase 3 randomized trial in China and other regions","volume":"33","author":"Yang","year":"2018","journal-title":"J. Gastroenterology Hepatology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1761301\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:00:32Z","timestamp":1775800832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1761301\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":55,"alternative-id":["10.3389\/fphar.2026.1761301"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1761301","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1761301"}}